Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 19.46% since last year same period to $169.06Mn in the Q3 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 9.29% jump in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit jumped 357.19% since last year same period to $17.31Mn in the Q3 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 170.87% jump in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin jumped 315.28% since last year same period to 10.24% in the Q3 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 164.84% jump in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.03 - a -56.92% fall from last quarter’s estimates.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.03.

Amicus Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Amicus Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.